Background The 69th World Health Assembly approved the Global Health Sector Strategy
to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality with the …

Background The 69th World Health Assembly approved the Global Health Sector Strategy
to eliminate viral hepatitis by 2030. Although no virological cure exists for hepatitis B virus (…

Background Since the release of the first global hepatitis elimination targets in 2016, and until
the COVID-19 pandemic started in early 2020, many countries and territories were making …

Background and Methods In preliminary trials, lamivudine, an oral nucleoside analogue, has
shown promise for the treatment of chronic hepatitis B. We conducted a one-year, double-…

Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest
rates of infection in Africa and Asia. Our understanding of the natural history of HBV infection …

This paper treats the problem of automatic fault diagnosis for systems with multiple faults.
The system is decomposed into n units u 1 , u 2 , . . . , u n , where a unit is a well-identifiable …

Large volume of new data on the natural history and treatment of chronic hepatitis B virus (HBV)
infection have become available since 2008. These include further studies in …

Background & Aims: One-year lamivudine therapy significantly suppressed hepatitis B virus
(HBV) replication, improved hepatic necroinflammatory activity, and prevented progression …

A study in Chinese patients with chronic hepatitis B showed that treatment with lamivudine
for 1 year significantly improves liver histology and enhances hepatitis B e antigen (HBeAg) …

During the course of chronic hepatitis B virus (HBV) infection, hepatitis B e antigen (HBeAg)
seroconversion to its antibody (anti-HBe) often coincides with normalization of liver …